ArticleImmunotherapy2021
Immunity to glycan α-Gal and possibilities for the control of COVID-19.
Article in Immunotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Ticked Off: Allergic Effector Cells in the Pathogenesis of Alpha-gal Syndrome.Current allergy and asthma reports · 2025Review
- Serum biomarkers for nutritional status as predictors in COVID-19 patients before and after vaccination.Journal of functional foods · 2023Article
- Allergic reactions associated with medically relevant arthropods.Annals of medicine · 2023Article
- Art-science multidisciplinary collaborations to address the scientific challenges posed by COVID-19.Annals of medicine · 2022Article
- Approaching Challenges Posed by SARS-CoV-2 Genetic Variants.Pathogens (Basel, Switzerland) · 2022Article
- Functional characterization of α-Gal producing lactic acid bacteria with potential probiotic properties.Scientific reports · 2022Article
- The Meat of the Matter: Understanding and Managing Alpha-Gal Syndrome.ImmunoTargets and therapy · 2022Review
- Probiotic Bacteria with High Alpha-Gal Content Protect Zebrafish against Mycobacteriosis.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.